50 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... • Hepatitis A virus ... Opportunistic #Infections #OIs ... #HIVAIDS #IDSA ... #management #pharmacology
Asthma Medications and Mechanism of Action

#Asthma #Medications #Drugs #Pulmonary #Pharmacology #Management #Treatment
Asthma Medications ... Mechanism of Action #Asthma ... Medications #Drugs #Pulmonary ... #Pharmacology # ... Management #Treatment
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... • Hepatitis A virus ... Opportunistic #Infections #OIs ... #HIVAIDS #IDSA ... #management #pharmacology
IDSA Aspergillosis Treatment
 • Invasive pulmonary aspergillosis (IPA)
 • CNS aspergillosis
 • Cardiac Aspergillus infection
 •
IDSA Aspergillosis ... Treatment • Invasive pulmonary ... Aspergillosis #Treatment #management ... #pharmacology # ... IDSA
Asthma Maintenance Therapy - Stepwise Approach 

Low dose ICS 
-> Low dose ICS/LABA or Med/High dose
Asthma Maintenance ... nonpharmacologic management ... Stepwise #Therapy #Management ... #Pharmacology # ... Pulmonary
Chart of Inhalers for Asthma and COPD
 - SABA - Short Acting Beta-2 Agonists
 - SAMA
of Inhalers for Asthma ... chart, this one is ... www.pyrls.com #inhalers #pulmonary ... #lung #asthma # ... #respiratory #pharmacology
The 2019 Global Initiative for Asthma (GINA) treatment strategy figure for adults and adolescents, annotated to
Initiative for Asthma ... long-acting β2-agonists; OCS ... #GINA #Asthma #Management ... #Stepwise #Pulmonary
Biologic therapy for eosinophilic asthma 
• Mepolizumab (Nucala) 
  • Anti-lL-5, 100 mg SQ q4
for eosinophilic asthma ... #eosinophilic #asthma ... #Medications #pharmacology ... #pulmonary #management
Here is a quick guide on the common direct-acting antivirals (DAAs) for chronic hepatitis C virus
Here is a quick ... chronic hepatitis C virus ... HepC #HepatitisC #Management ... #Pharmacology
Outpatient Treatment of with Community-Acquired Pneumonia (CAP)
No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa:
pneumococcal resistance is ... fluoroquinolone #IDSA ... Treatment #Regimen #Management ... #Guidelines #pharmacology